SG11201911031TA - Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells - Google Patents

Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells

Info

Publication number
SG11201911031TA
SG11201911031TA SG11201911031TA SG11201911031TA SG11201911031TA SG 11201911031T A SG11201911031T A SG 11201911031TA SG 11201911031T A SG11201911031T A SG 11201911031TA SG 11201911031T A SG11201911031T A SG 11201911031TA SG 11201911031T A SG11201911031T A SG 11201911031TA
Authority
SG
Singapore
Prior art keywords
microorganisms
programmed
tumor cells
cancer therapeutics
immune modulators
Prior art date
Application number
SG11201911031TA
Inventor
Adam Fisher
Ning Li
Jose Lora
Original Assignee
Synlogic Operating Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2018/012698 external-priority patent/WO2018129404A1/en
Application filed by Synlogic Operating Co Inc filed Critical Synlogic Operating Co Inc
Publication of SG11201911031TA publication Critical patent/SG11201911031TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001141—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/104—Aminoacyltransferases (2.3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2497—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing N- glycosyl compounds (3.2.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04001—Cytosine deaminase (3.5.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
SG11201911031TA 2017-07-12 2018-07-11 Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells SG11201911031TA (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201762531784P 2017-07-12 2017-07-12
US201762543322P 2017-08-09 2017-08-09
US201762552319P 2017-08-30 2017-08-30
US201762592317P 2017-11-29 2017-11-29
US201762607210P 2017-12-18 2017-12-18
PCT/US2018/012698 WO2018129404A1 (en) 2017-01-06 2018-01-05 Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
US201862628786P 2018-02-09 2018-02-09
US201862642535P 2018-03-13 2018-03-13
US201862657487P 2018-04-13 2018-04-13
US201862688852P 2018-06-22 2018-06-22
PCT/US2018/041705 WO2019014391A1 (en) 2017-07-12 2018-07-11 Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells

Publications (1)

Publication Number Publication Date
SG11201911031TA true SG11201911031TA (en) 2020-01-30

Family

ID=65002257

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201911031TA SG11201911031TA (en) 2017-07-12 2018-07-11 Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells

Country Status (10)

Country Link
US (1) US20200149053A1 (en)
EP (1) EP3651782A1 (en)
JP (1) JP2020527025A (en)
KR (1) KR20200064980A (en)
CN (1) CN111246865A (en)
AU (1) AU2018301668A1 (en)
CA (1) CA3066109A1 (en)
IL (1) IL270892A (en)
SG (1) SG11201911031TA (en)
WO (1) WO2019014391A1 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3402498A1 (en) 2016-01-11 2018-11-21 Synlogic, Inc. Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
BR112019013863A2 (en) 2017-01-06 2020-03-03 Synlogic Operating Company, Inc. MICRO-ORGANISMS PROGRAMMED TO PRODUCE IMMUNE AND ANTICANCER THERAPEUTIC MODULATORS IN TUMOR CELLS
BR112019018915A2 (en) 2017-03-15 2020-04-14 Pandion Therapeutics Inc targeted immunotolerance
MX2019013517A (en) 2017-05-24 2020-08-17 Pandion Operations Inc Targeted immunotolerance.
CA3069523A1 (en) 2017-07-11 2019-01-17 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
US11458172B2 (en) 2017-09-08 2022-10-04 New Portal Limited Nucleic acid systems that enable bacteria to specifically target solid tumors via glucose-dependent viability
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
CN109536444B (en) * 2018-12-11 2022-06-28 吉林省拓华生物科技有限公司 Separation induction method suitable for malignant solid tumor infiltrating T lymphocytes
JP2022524951A (en) * 2019-02-27 2022-05-11 アクティム・セラピューティクス・インコーポレイテッド Tumors, tumor-resident immune cells and immunostimulatory bacteria engineered to colonize the tumor microenvironment
US20200270613A1 (en) * 2019-02-27 2020-08-27 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
US20220257732A1 (en) 2019-04-29 2022-08-18 Synlogic Operating Company, Inc. Enumeration of genetically engineered microorganisms by live cell counting techniques
US11739146B2 (en) 2019-05-20 2023-08-29 Pandion Operations, Inc. MAdCAM targeted immunotolerance
CN110747154A (en) * 2019-09-17 2020-02-04 广州维生君生物科技有限公司 PD-1 humanized single-chain antibody fusion gene transformed lactic acid bacteria and application thereof
CN110904002B (en) * 2019-11-25 2022-04-29 天津大学 Method for biologically removing tetracycline antibiotics
CN111088197B (en) * 2020-01-20 2021-07-23 华南农业大学 Provevelis alcaligenes and application thereof in degrading tetracycline and producing auxin
AU2021220986A1 (en) * 2020-02-13 2022-09-01 The Johns Hopkins University Recombinant therapeutic interventions for cancer
CN111849805B (en) * 2020-06-17 2022-04-22 天津科技大学 Pediococcus acidilactici with cervical cancer resistance effect and application thereof
WO2022006748A1 (en) * 2020-07-07 2022-01-13 New Portal Limited Genetically engineered live bacteria and methods of constructing the same
CN116113425A (en) * 2020-07-07 2023-05-12 丹麦科技大学 Bacterial vectors for engineering non-phagocytic immune cells
CN111893074B (en) * 2020-08-14 2022-05-20 贵州大学 Bacillus fusiformis strain and application thereof
CN112410365B (en) * 2020-10-21 2022-08-26 山东大学 Burkholderia homologous recombination system and application thereof
WO2022094865A1 (en) * 2020-11-05 2022-05-12 中国科学院深圳先进技术研究院 "autolytic" salmonella strain, preparation method therefor and application thereof in tumor treatment
US20240041945A1 (en) * 2020-11-05 2024-02-08 Shenzhen Institutes Of Advanced Technology Chinese Academy Of Sciences Method for constructing strictly anaerobic salmonella, constructed strictly anaerobic salmonella and application thereof
CN112342233B (en) * 2020-11-10 2022-08-26 上海陶宇晟生物技术有限责任公司 Polynucleotide for increasing c-di-AMP production when bacteria express DacA
CA3200887A1 (en) 2020-12-02 2022-06-09 Michael James Engineered microorganisms
CN114196564B (en) * 2021-10-08 2023-02-14 沈阳农业大学 Tetragenococcus halophilus and application thereof in production of anti-cancer extracellular polysaccharide
WO2023076988A1 (en) * 2021-10-27 2023-05-04 University Of Cincinnati Engineered bacteria and methods of use in tumor remodeling
CN114317347B (en) * 2021-12-28 2023-11-07 武汉科缘生物发展有限责任公司 Bacillus coagulans and application thereof, composition and fermentation culture method of bacillus coagulans
CN115895989A (en) * 2022-08-05 2023-04-04 湖北工业大学 Escherichia coli with high succinic acid yield as well as preparation method and application thereof
US20240091351A1 (en) * 2022-09-21 2024-03-21 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ATE192037T1 (en) * 1989-12-29 2000-05-15 Braun Medical Inc USE OF ARGININE AS AN IMMUNE STIMULATOR
GB9107305D0 (en) 1991-04-08 1991-05-22 Unilever Plc Probiotic
US6203797B1 (en) 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
EP1034787A1 (en) 1999-03-11 2000-09-13 Société des Produits Nestlé S.A. Lactobacillus strains preventing diarrhea caused by pathogenic bacteria
NZ518354A (en) * 1999-10-04 2005-02-25 Vion Pharmaceuticals Inc Compositions and methods for tumor-targeted delivery of effector molecules
US6962696B1 (en) * 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
AU2002257420A1 (en) 2001-05-01 2002-11-11 National Research Council Of Canada A system for inducible expression in eukaryotic cells
AU2002356962C1 (en) * 2001-12-12 2008-05-01 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation
US7731976B2 (en) 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
EP2655624B1 (en) 2010-12-23 2017-11-29 Biogen MA Inc. Linker peptides and polypeptides comprising same
CN104136037B (en) 2012-01-17 2018-02-23 小利兰·斯坦福大学托管委员会 High-affinity SIRP α reagents
EP2894985A4 (en) 2012-09-13 2016-09-28 Massachusetts Inst Technology Programmable drug delivery profiles of tumor-targeted bacteria
BR112016004095A2 (en) 2013-08-30 2017-10-17 Univ Texas administration of quinurenine depletion enzymes for tumor therapy
WO2016183532A1 (en) * 2015-05-13 2016-11-17 Synlogic, Inc. Bacteria engineered to treat a disease or disorder
US9688967B2 (en) 2014-12-05 2017-06-27 Synlogic, Inc. Bacteria engineered to treat diseases associated with hyperammonemia
BR112017011923A2 (en) * 2014-12-05 2018-02-27 Synlogic Inc bacteria modified to treat diseases associated with hyperammonemia
WO2016106178A1 (en) * 2014-12-24 2016-06-30 The Uab Research Foundation, Inc. Multitargeting onocolytic adenovirus, methods of use, and methods of making
CA3013713A1 (en) * 2015-02-11 2016-08-18 The Johns Hopkins University Bacteria over-expressing c-di-amp and therapeutic methods
EP3402498A1 (en) 2016-01-11 2018-11-21 Synlogic, Inc. Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
BR112019013863A2 (en) * 2017-01-06 2020-03-03 Synlogic Operating Company, Inc. MICRO-ORGANISMS PROGRAMMED TO PRODUCE IMMUNE AND ANTICANCER THERAPEUTIC MODULATORS IN TUMOR CELLS

Also Published As

Publication number Publication date
AU2018301668A1 (en) 2019-12-19
JP2020527025A (en) 2020-09-03
IL270892A (en) 2020-01-30
KR20200064980A (en) 2020-06-08
CA3066109A1 (en) 2019-01-17
CN111246865A (en) 2020-06-05
US20200149053A1 (en) 2020-05-14
WO2019014391A1 (en) 2019-01-17
EP3651782A1 (en) 2020-05-20

Similar Documents

Publication Publication Date Title
IL270892A (en) Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
IL267830A (en) Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
ZA201808564B (en) Improvements in and relating to garment refreshment
ZA201808563B (en) Improvements in and relating to garment refreshment
HK1251013A1 (en) Histamine-producing bacterial strains and their use in cancer
IL267766A (en) Immune cells with modified metabolism and their use thereof
GB201600746D0 (en) Improvements in and relating to polymer materials
GB2550980B (en) Improvements in or relating to buoys and/or SARTs
GB201512315D0 (en) Improvements in and relating to beds
ZA201801302B (en) Novel microorganisms and their use in agriculture
GB2567895B (en) Improvements in and relating to sonar
GB2555814B (en) Improvement in and relating to catalysis
GB2547863B (en) Improvements in and relating to servo valves
GB201712544D0 (en) Improvements in and relating to contructional toy elements
GB2565485B (en) Improvements in and relating to piling cages
GB2556250B (en) Improvements in or relating to buoys and/or SARTs
GB201707316D0 (en) Improvements in and relating to animation techniques
AU367247S (en) Bag
GB201602081D0 (en) Improvement in and relating to beds
GB201511158D0 (en) Cell modification and application in therapy
GB201514073D0 (en) Method to enhance colouring in colouring books
GB201513116D0 (en) Improvements in and relating to plastics
GB201514431D0 (en) Improvements in and relating to materials
GB201506463D0 (en) Improvements in and relating to polymer materials - II
GB201506453D0 (en) Improvements in and relating to polymer materials - I